SKYE (Skye Bioscience) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SKYE Skye Bioscience Inc SKYE
32 GF Score
Price $0.66
! 1 Warning Sign
View Full Analysis

What is Skye Bioscience FFO?

FFO (Funds from operations) only applies to REITs.

SKYE
32GF Score
Skye Bioscience Inc SKYE
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Skye Bioscience Business Description

Other Exchanges 09R:Germany
Address 11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
32GF Score

Get the complete analysis for SKYE

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.66
Price